Dr Michael Buschle, CSO & president - biologics, Glenmark Pharmaceuticals
The company enters oncology with the discovery and the initiation of IND enabling studies of this innovative bispecific antibody GBR 1302.
This is the first bispecific antibody based on Glenmark's proprietary BEAT platform, said the company's press statement.
The antibody was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland.
Commenting on this milestone, Dr Michael Buschle, CSO and president - Biologics, Glenmark Pharmaceuticals said, "GBR 1302 is significant for Glenmark on multiple levels. It is our first bispecific antibody. It is our first antibody based on our proprietary BEAT antibody engineering platform and it represents the entry of Glenmark into the oncology innovator space, which has a huge commercial potential."
The discovery is based on Glenmark's innovative BEAT antibody technology platform which facilitates the efficient development and manufacture of antibodies with dual specificities termed, bispecific antibodies.